Alamar Biosciences Expands Executive Leadership for Growth Phase

Alamar Biosciences Strengthens Leadership to Drive Future Growth

In a strategic move to bolster its executive team, Alamar Biosciences, a company renowned for its precision proteomics, announced significant leadership changes aimed at driving the next phase of the organization’s growth. This announcement, made on October 16, 2025, highlights the firm's commitment to innovation, operational excellence, and strategic development in the healthcare landscape.

Key Developments in Leadership

Promotion of Tod White to President

Alamar Biosciences has elevated Tod White, JD, to the position of President. Since joining the company, White has played a pivotal role in shaping its trajectory. He has led critical areas, including finance, human resources, investor relations, fundraising, business development, and legal matters. His promotion recognizes not only the breadth of his impact but also the trust the board has in his ability to guide Alamar as it enters a new chapter.

Yuling Lu, the founder, chairwoman, and CEO of Alamar Biosciences, expressed her confidence in White, stating, "Tod has been a cornerstone of our leadership. His ability to navigate complexity and drive cross-functional collaboration has been pivotal to our success. This promotion reflects the board's faith in his vision and leadership in expanding our operations and deepening our impact."

Appointment of Justin McAnear as CFO

To further strengthen its financial leadership, Alamar welcomes Justin McAnear as its new Chief Financial Officer. McAnear brings over 25 years of operational and financial leadership experience across various sectors. His previous role as CFO at 10x Genomics, where he was instrumental in the company's initial public offering (IPO) in 2019, adds valuable expertise to Alamar's executive team. He also held the vice president position for global finance at Tesla for over three years, contributing to significant initiatives such as the launch of the Model X and Model 3.

"Justin’s arrival marks an exciting moment for Alamar. He brings a rare combination of strategic insight, operational discipline, and an in-depth understanding of scaling complex organizations," stated Lu. "I look forward to collaborating with him on our next growth and development phase."

A Collaborative Approach to Leadership

Together, White and McAnear provide complementary strengths that will help Alamar navigate the opportunities ahead. Their collective expertise reinforces the company's commitment to innovation, integrity, and superior performance within the industry.

About Alamar Biosciences

Alamar Biosciences, Inc. is a private life sciences company dedicated to advancing precision proteomics to enable the earliest possible disease detection. Its proprietary NULISA™ platform, along with the ARGO™ HT system, seamlessly integrates with the latest genomic advancements, achieving single-digit attomolar sensitivity that significantly outperforms the most sensitive protein detection technology available today. For further information, visit alamarbio.com.

Looking Ahead

With these key appointments, Alamar Biosciences is poised for an exciting future, ready to innovate and expand its impact in the field of disease detection. The leadership team's vision and drive are expected to foster a landscape of advancements that will benefit healthcare professionals and patients alike.